Across TCGA pan-cancer cohorts, CYCSP46 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of CYCSP46’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where CYCSP46 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CYCSP46 is over-expressed in tumor.
LUAD are the cancer types where CYCSP46 tumor–normal differential expression is most reproducible.